Prediction of Virologic Outcome of Salvage Antiretroviral Treatment by Different Systems for Interpreting Genotypic HIV Drug Resistance
暂无分享,去创建一个
F. Maggiolo | D. Ripamonti | A. Callegaro | F. Suter | M. Airoldi | G. Gregis | G. Quinzan | V. Ravasio | E. Bombana
[1] A. Blaxhult,et al. Concomitant Use of an Active Boosted Protease Inhibitor with Enfuvirtide in Treatment-Experienced, HIV-Infected Individuals: Recent Data and Consensus Recommendations , 2006, HIV clinical trials.
[2] J. Montaner,et al. Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials , 2005, Journal of acquired immune deficiency syndromes.
[3] F. Chiodo,et al. Variability in the Interpretation of Transmitted Genotypic HIV-1 Drug Resistance and Prediction of Virological Outcomes of the Initial Haart by Distinct Systems , 2004, Antiviral therapy.
[4] C. Tinelli,et al. Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients. , 2003, The Journal of infectious diseases.
[5] P. Narciso,et al. Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. , 2003, Journal of Infectious Diseases.
[6] J. Montaner,et al. Discrepant results in the interpretation of HIV‐1 drug‐resistance genotypic data among widely used algorithms , 2003, HIV medicine.
[7] F. Brun-Vézinet,et al. Predictors of the Virological Response to a Change in the Antiretroviral Treatment Regimen in HIV-1-Infected Patients Enrolled in a Randomized Trial Comparing Genotyping, Phenotyping and Standard of Care (Narval Trial, Anrs 088) , 2002, Antiviral therapy.
[8] B. Schmidt,et al. Genotypic drug resistance interpretation systems--the cutting edge of antiretroviral therapy. , 2002, AIDS reviews.
[9] S. Staszewski,et al. Comparison of Nine Resistance Interpretation Systems for HIV-1 Genotyping , 2002, Antiviral therapy.
[10] S. Hammer,et al. HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients , 2002, AIDS.
[11] A. Vandamme,et al. A Genotypic Drug Resistance Interpretation Algorithm that Significantly Predicts Therapy Response in HIV-1-Infected Patients , 2001, Antiviral therapy.
[12] V. Arendt,et al. Genotypic Correlates of Resistance to HIV-1 Protease Inhibitors on Longitudinal Data: The Role of Secondary Mutations , 2000, Antiviral therapy.
[13] F. Hecht,et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population , 2000, AIDS.
[14] T. Perneger,et al. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. , 1999, AIDS.
[15] D G Seymour,et al. Making better decisions: construction of clinical scoring systems by the Spiegelhalter-Knill-Jones approach. , 1990, BMJ.
[16] F. Maggiolo,et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.